연구용

PD 98059 MEK 억제제

Name: PD 98059
Brand: Selleck Chemicals
SKU: S1177
Rating: 5 (518 reviews)

제품 번호S1177

PD98059는 세포 없는 분석에서 IC50이 2 μM인 비-ATP 경쟁적 MEK 억제제로, MEK-1 매개 MAPK 활성화를 특이적으로 억제합니다. ERK1 또는 ERK2를 직접 억제하지 않습니다. PD98059는 아릴 탄화수소 수용체(AHR)의 리간드이며 AHR 길항제로 기능합니다.

화학 구조

분자량: 267.28

바로가기

품질 관리

배치: 순도: 99.92%

99.92

관련 타겟	ERK p38 MAPK Raf JNK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase
기타 MEK 억제제	PD0325901 (Mirdametinib) U0126-EtOH PD184352 (CI-1040) BIX 02189 Pimasertib (AS-703026) Refametinib (RDEA119) TAK-733 AZD8330 SL-327 BIX 02188

세포 배양, 처리 및 작업 농도

세포주	분석 유형	농도	배양 시간	제형	활성 설명	PMID
TE4	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
MKN7	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
OE19	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
NCI-N87	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
KATOIII	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
NUGC3	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
NUGC2	Function Assay	50 μM	48 h	DMSO	increases expression of HLA-A02 or HLA-A24 molecules	24244023
SGC-7901	Apoptosis Assay	20 μM	24 h		inhibits CP-mediated apoptosis	24241351
MG-63	Function Assay	20 μM	0.5 h		blocks the CH-induced phosphorylated ELK1 protein expression	24239640
ARPE-19	Function Assay	20 μM	0.5 h		inhibits Apelin-induced phosphorylation of Erk and Akt	24227918
CRL-2302	Function Assay	20 μM	0.5 h		inhibits Apelin-induced phosphorylation of Erk and Akt	24227918
MCF-7	Apoptosis Assay	20 μM	1 h		increases caspase-9 enzyme activity	24216289
MCF-7	Function Assay	20 μM	1 h		abolishes expression of phosphorylated ERK co-treatment with conjugate	24216289
7402	Apoptosis Assay	30 μM	5 d		decreases cell proliferation	24211253
HT-29	Function Assay	20 μM	48 h		reduces the BNIP3 expression pre-treated with 5-aza-dC	24211581
DLD-1	Function Assay	20 μM	48 h		reduces the BNIP3 expression pre-treated with 5-aza-dC	24211581
7721	Apoptosis Assay	30 μM	5 d		decreases cell proliferation	24211253
SGC7901	Apoptosis Assay	50 μM	24/48/72 h	DMSO	induces apoptosis combined with JAK2 shRNA	24178240
SMMC7721	Function Assay	25/50 μM	24 h		suppresses the expression of p-Akt or p-ERK1/2	24168056
MCF-7	Growth Inhibition Assay	10 μM	48h	DMSO	reverses BNF-induced cell cycle arrest	24163404
Caco-2	Function Assay	50 μM	48h	DMSO	enhances the mRNA levels of SCNN1A,FXYD3, LCT, LOX, HIF3A, ZG16, PDE6A and LGALS16 genes co-treated with Dex	24161695
HAECs	Function Assay	10 μM	1 h		attenuates TNF-α-stimulated ICAM-1 and VCAM-1 expression	24134657
Ca9-22	Function Assay	3 μM	1 h		abolishes the ability of HbR to induce IL-8 production	24126532
Ca9-22	Function Assay	3 μM	1/2 h		reduces HbR-induced ATF-2 phosphorylation	24126532
AGS	Function Assay	10 μM	0.5 h		inhibits the upregulation of the IL-8 gene	24106166
Caco-2	Apoptosis Assay	10 μM	24 h		decreases cell apoptosis induced by 5-FU	24095863
A549	Function Assay	50 μM	2 h		blocks ERK phosphorylation mediated by 1,2-NQ	24067727
HPMC	Function Assay	10 μM	48 h		reverses the changes in cell morphology induced by HGPDS	24042838
HCT-8	Apoptosis Assay	10 μM	24 h		decreases cell apoptosis induced by 5-FU	24095863
HPMC	Apoptosis Assay	10 μM	24 h		reverses decrease in cell viability induced by HGPDS	24042838
MGC803	Apoptosis Assay	20 μM	1 h		inhibits apoptosis induced by IFN-α and 5′-DFUR	24027750
SGC7901	Apoptosis Assay	20 μM	1 h		inhibits apoptosis induced by IFN-α and 5′-DFUR	24027750
G292	Apoptosis Assay	30 μM	2 h		restores capsaicin-induced cell death	24012930
COLO205	Apoptosis Assay	10/20/40 μM	24 h		induces DNA ladder formation	24019108
BxPC-3	Function Assay	10 μM	6 h		increase miR-143 expression	23973710
HPAF-II	Function Assay	10 μM	6 h		increase miR-143 expression	23973710
HepG2	Function Assay	40 μM	6/12 h		inhibits the increase of p-ERK1 and p-c-Jun protein expression by PL	23942851
HL-60	Apoptosis Assay	50 μM	1 h		rescues BA145 mediated apoptosis	23948751
LNCaP	Function Assay	10 μM	1 h		decreases the EGF upregulated p-YB-1	23838318
HUVECs	Function Assay	25 μM	1 h		increase NF-κB p65 nuclear translocation	23901008
HL60	Function Assay	20 μM	72 h	DMSO	inhibits -induced CD11b expression	23825585
NB4	Function Assay	10 μM	72 h	DMSO	inhibits -induced CD11b expression	23825585
EPOR/CR3	Function Assay	50 μM	3 h		reduces EPO and/or IL-3-induced the tyrosine phosphorylation	23820731
HUASMCs	Function Assay	10 μM	24 h		inhibits Ang II-induced ERK1/2 phosphorylation level	23816468
HUASMCs	Function Assay	10 μM	24 h		diminishes Ang II-caused SOCS3 mRNA and protein expression	23816468
SGC7901	Function Assay	10 μM	24 h		inhibits the expression of phosphorylated ERK1/2	23792588
MKN45	Growth Inhibition Assay	10 μM	24/48/72 h		inhibits cell growth co-treated with DAPT	23792588
SGC7901	Growth Inhibition Assay	10 μM	24/48/72 h		inhibits cell growth co-treated with DAPT	23792588
MKN45	Function Assay	10 μM	24 h		inhibits the expression of phosphorylated ERK1/2	23792588
SGC7901	Apoptosis Assay	10 μM	24 h		increases the DAPT-induced cell apoptosis	23792588
MKN45	Apoptosis Assay	10 μM	24 h		increases the DAPT-induced cell apoptosis	23792588
BxPC-3 cells	Growth Inhibition Assay	20 μM	0.5 h		inhibits VEGF-A-regulated HUVEC growth and tube formation induced by PAR-2 AP	23764046
NB4	Apoptosis Assay	10/20/60 μM	1.5 h	DMSO	decreases cell viability co-treated	23735541
HepG2	Function Assay	20 μM	24 h		inhibits the HO-1 protein expression co-treated	23707609
HUVECs	Apoptosis Assay	2/4 μM	24/48 h		induces cell death	23707520
KG-1	Apoptosis Assay	20 μM	12 h		enhances cell apoptosis induced by S1	23706691
AML 1#	Apoptosis Assay	20 μM	12 h		enhances cell apoptosis induced by S1	23706691
A2780	Function Assay	20 μM	1 h		blocks DTCD-induced DR5 expression	23696862
KYSE30	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
TE5	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
TE1	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
TE3	Function Assay	50 μM	48 h	DMSO	upregulates the expression of HLA class I	24244023
KYSE30	Function Assay	20/50/100 μM	48 h	DMSO	inhibits p-Erk and wortmannin downregulated p-Akt in a dose-dependent manner	24244023
TE1	Function Assay	20/50/100 μM	48 h	DMSO	inhibits p-Erk and wortmannin downregulated p-Akt in a dose-dependent manner	24244023
TE4	Function Assay	20/50/100 μM	48 h	DMSO	inhibits p-Erk and wortmannin downregulated p-Akt in a dose-dependent manner	24244023
HT29	Function Assay	10 μM	2 h		inhibits of JAK2, ERK1/2 and STAT3 phosphorylation	24265293
HepG2	Apoptosis Assay	20 μM	24 h		inhibits ERK1/2 phosphorylation and enhances VB1-induced apoptosis	24247909
HepG2	Function Assay	20 μM	2 h		enhances VB1-induced FOXO3a transcriptional activity	24247909
MC-3	Apoptosis Assay	10 μM	24 h		potentiated MESC-induced apoptosis in cells	24270523
Raji	Function Assay	10 μM	1 h		blocks hsBAFF induced Erk1/2 phosphorylation	24269630
Raji	Growth Inhibition Assay	10 μM	1 h		inhibits the basal or hsBAFF-stimulated cell proliferation and viability	24269630
A549	Function Assay	30 μM	0.5 h	DMSO	inhibits thrombin-induced C/EBPβ Thr235 phosphorylation	24277696
HCSMCs	Growth Inhibition Assay	10 μM	24 h		blocks FABP4-induced HCASMC proliferation	24312381
PANC-1	Function Assay	20 μM	48 h		inhibits the expression of Δ6D in response to the PPARδ agonist	24294133
A549	Function Assay	30 μM	0.5 h	DMSO	inhibits the thrombin-induced IL-8/CXCL8-Luc activity	24277696
SW480	Function Assay	10 μM	20 h	DMSO	suppresses the CRT activity	24324366
HEK 293	Function Assay	10 μM	5 h	DMSO	inhibits Wnt-induced β-catenin/TCF4 activity and nuclear β-catenin accumulation	24324366
HEK 293	Function Assay	10 μM	5 h	DMSO	suppresses the CRT activity	24324366
HL-60	Function Assay	10/20 μM	1 h		inhibits the N. chinensisextract induced differentiation into granulocytes	24357020
HL-60	Function Assay	2 µM	16 h	DMSO	inhibits the association of pS621 Raf-1 and NFATc3, and the RA-induced phosphorylation of nuclear NFATc3	24330068
HeLa	Function Assay	50 μM	0.5 h		blocks TRX-1 nuclear migration and TXNIP down-regulation	24376827
HUVECs	Function Assay	10 μM	1 h		inhibits the HDL reduced COX-2 expression and PGI-2 release	24385109
MCF-7	Function Assay	10 μM	10/30 min		reduces the UTP-dependent ERK phosphorylation	24390819
HGC-27	Apoptosis Assay	1 µM	1 h		suppresses RAD001 plus MK-2206-induced cell viability loss	24416349
PC3	Apoptosis Assay	50 μM	0.5 h		inhibits MHY-449-induced apoptosis	24424889
HPAEpiCs	Function Assay	30 μM	1 h		inhibits TNF-α stimulated p42/p44 MAPK phosphorylation	24441870
BeWo	Function Assay	10 μM	2 h		inhibits ERK1/2	24433846
A498	Apoptosis Assay	50 μM	24 h		potentiates the pro-apoptotic effects of NC	24508476
NHBE	Function Assay	2/20 μM	2 h		attenuates IL-33 stimulated CXCL8/IL-8 secretion	24479526
A375	Cell Invasion Assay	10–20 µM	24 h		reduces melanoma cell invasion	24466036
HBMEC	Function Assay	10 μM	1 h		blocks VEGF-induced EphA2 expression	24458982
HCT-15	Function Assay		1 h		attenuates PGE2-induced phosphorylation of Erk	25431425
HCT-15	Apoptosis Assay		1 h		abolishes the protective effects of PGE2 against curcumin-induced apoptosis	25431425
786-O	Apoptosis Assay	50 μM	24 h		potentiates the pro-apoptotic effects of NC	24508476
HepG2	Growth Inhibition Assay	20 μM	24 h		suppresses TGF-β1-induced cell proliferation and invasion	25560488
SW480	Function Assay	20 μM	1 h		reduces the expression of ATF3 protein	25447816
MDA-MB-231	Function Assay	25 μM	2-3 h		decreases p-ERK1/2 and S100A4 expression	25555875
HepG2	Function Assay	10 μM	5 h		blocks phosphorylated MAPKs induced by exogenous TGF-β1	25560488
MCF-7	Function Assay	10 μM	1 h		inhibits IL-18-enhanced cell migration	25727011
H1355	Function Assay	25 μM	1 h		blunts the B[a]P-induced increase in phospho-Chk1 and phospho-ERK expression	25769181
PC12	Function assay				Inhibition of nerve growth factor-mediated MAP kinase activity in human PC12 cells, IC50 = 2 μM.	18077363
HT-29	Antiproliferative assay		5 days		Antiproliferative activity against human HT-29 cells after 5 days by WST1 assay, IC50 = 4 μM.	25078316
IEC6	Function assay		5 mins		Inhibition of MEK1/2 in rat IEC6 cells assessed as reduction in ERK1/2 loop phosphorylation dosed 30 mins before to stimulation with 10% serum for 5 mins by immunoblotting method, IC50 = 4.2 μM.	25078316
NG 108-15	Function assay				Concentration required to abolish MAPK activity in mouse neuroblastoma and rat glioma hybrid NG 108-15 cells, Activity = 10 μM.	15537354
PC12	Function assay	10 uM	5 hrs		Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with JNK inhibitor SP600125 for 1 hr before compound addition by Western blot analysis	21345685
PC12	Function assay	10 uM	5 hrs		Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with MEK2 inhibitor U0126 for 1 hr before compound addition by Western blot analysis	21345685
PC12	Function assay	10 uM	5 hrs		Activation of Nrf2/ARE in rat PC12 cells assessed as HO-1 protein induction at 10 uM after 5 hrs pretreated with MEK1 inhibitor PD98059 for 1 hr before compound addition by Western blot analysis	21345685
HeLa	Function assay	20 uM	3 hrs		Inhibition of ERK1/2 phosphorylation in human HeLa cells at 20 uM after 3 hrs by Western blotting analysis	23570615
RD	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
NB1643	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
RD	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	29435139
SK-N-MC	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
TC32	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
MDA-MB-231	Function assay	50 uM			Downregulation of MMP2 in human MDA-MB-231 cells at 50 uM by Western blot analysis	22926226
MDA-MB-231	Function assay	50 uM			Downregulation of MMP9 in human MDA-MB-231 cells at 50 uM by Western blot analysis	22926226
클릭하여 더 많은 세포주 실험 데이터 보기

화학 정보, 보관 및 안정성

분자량	267.28	화학식	C₁₆H₁₃NO₃	보관 (수령일로부터)	3년-20°C분말
CAS 번호	167869-21-8	SDF 다운로드		원액 보관	1년-80°C용매에 보관 1개월-20°C용매에 보관
동의어	N/A			Smiles	COC1=CC=CC(=C1N)C2=CC(=O)C3=CC=CC=C3O2

용해도

In vitro
배치:

DMSO : 46 mg/mL (172.1 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 53 mg/mL (198.29 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 14 mg/mL (52.37 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 28 mg/mL (104.75 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 14 mg/mL (52.37 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : Insoluble

Ethanol : Insoluble

몰농도 계산기

질량	농도	부피	분자량
=	×	×

희석 계산기 분자량 계산기

In vivo 배치:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	4%DMSO 1 30%PEG300 2 5%Tween80 3 61%ddH2O Selleck 연구소에서 검증되었습니다. 이 제형에 대한 조정이 필요한 경우 맞춤 테스트를 위해 당사 영업팀에 문의하십시오.	1.000mg/ml (3.74mM)	Taking the 1 mL working solution as an example, add 40 μL 25 mg/ml clarified DMSO stock solution to 300 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 610 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Selleck 연구소에서 검증되었습니다. 이 제형에 대한 조정이 필요한 경우 맞춤 테스트를 위해 당사 영업팀에 문의하십시오.	1.000mg/ml (3.74mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

생체 내 제형 계산기 (투명한 용액)

1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)

투여량: mg/kg 동물 평균 체중: g 동물당 투여량:μL 동물 수:

2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

계산 결과:

작업 농도: mg/ml;

DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH₂O, 혼합하고 투명하게 합니다.

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.

참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.

작용 메커니즘

특징	Does not inhibit c-Raf phosphorylated MEK1.
Targets/IC₅₀/Ki	AhR (Cell-free assay) 1 μM MEK1 (Cell-free assay) 2 μM
시험관 내(In vitro)	PD98059는 세린 잔기 218 및 222를 글루타메이트로 돌연변이시켜 생성된 기저 MEK1 또는 부분적으로 활성화된 MEK(MEK-2E)를 IC50 2 μM으로 억제합니다. 이 화합물은 MAPK 상동체 JNK 및 P38을 억제하지 않습니다. Raf 키나아제, cAMP 의존성 키나아제, 단백질 키나아제 C, v-Src, 표피 성장 인자(EGF) 수용체 키나아제, 인슐린 수용체 키나아제, PDGF 수용체 키나아제 및 포스파티딜이노시톨 3-키나아제를 포함한 여러 다른 키나아제 활성을 억제하지 않으므로 MEK에 대해 고도로 선택적입니다. 이 억제제는 PDGF 자극 MAPK 활성화 및 3T3 세포로의 티미딘 통합을 각각 약 10 μM 및 약 7 μM의 IC50로 억제합니다. Raf 또는 MEK 키나아제에 의한 MEK1 활성화를 4 μM의 IC50로 강력하게 억제하고, Raf에 의한 MEK2 활성화를 50 μM의 IC50로 약하게 억제합니다. 이 화학 물질은 KB 및 PC12 세포에서 스트레스 및 인터루킨-1 자극 키나아제 캐스케이드에 참여하는 MEK 상동체 MKK4 및 RK 키나아제의 활성화와 Swiss 3T3 세포에서 인슐린 또는 표피 성장 인자에 의한 p70 S6 키나아제의 활성화를 억제하지 않습니다. 세포 생존력을 변경하지 않고 신경 성장 인자(NGF) 유도 PC12 세포 분화를 완전히 차단합니다. 이 화합물은 RANKL을 포함하는 배양액에서 RAW264.7 세포의 증식을 용량 의존적으로 억제하여 TRAP 양성 세포의 명백한 감소를 초래합니다.
키나아제 분석	시험관 내 MEK 억제 활성
키나아제 분석	미엘린 기본 단백질(MBP)로의 ³²P 통합은 44-kDa MAPK(GST-MAPK) 또는 45-kDa MEK(GST-MEK1)를 함유하는 글루타티온 S-트랜스퍼라제(GST) 융합 단백질의 존재 하에 분석됩니다. 분석은 50 μL의 50 mM Tris, pH 7.4/10 mM MgCl₂/2 mM EGTA/10 μM [γ-³²P]ATP에 10 μg의 GST-MEK1, 0.5 μg의 GST-MAPK 및 40 μg의 MBP를 포함하여 수행됩니다. 30°C에서 15분 동안 인큐베이션한 후, Laemmli SDS 샘플 버퍼를 첨가하여 반응을 중단합니다. 인산화된 MBP는 SDS/10% PAGE로 분리됩니다.
생체 내(In vivo)	국소 뇌 허혈 30분 전 마우스에 PD98059를 처리하면 손상으로부터 보호하여 경색 부피가 감소합니다. 이 화합물로 30분 전 전처리한 후 3시간 동안 시간당 세룰레인 주사와 함께 처리하면 췌장 습중량 및 조직학을 기반으로 세룰레인 유발 급성 췌장염이 유의하게 개선됩니다. 카라기난 1시간 후 마우스에 이 화학 물질(10 mg/kg)을 투여하면 측정된 모든 염증 매개변수가 감소합니다.
참조	[1] https://pubmed.ncbi.nlm.nih.gov/7644477/ [2] https://pubmed.ncbi.nlm.nih.gov/7499206/ [3] https://pubmed.ncbi.nlm.nih.gov/7775407/ [4] https://pubmed.ncbi.nlm.nih.gov/12237315/ [5] https://pubmed.ncbi.nlm.nih.gov/10536014/ [6] https://pubmed.ncbi.nlm.nih.gov/12370536/ [7] https://pubmed.ncbi.nlm.nih.gov/20074457/ [8] https://pubmed.ncbi.nlm.nih.gov/11254111/ [9] https://pubmed.ncbi.nlm.nih.gov/17161815/ [10] https://pubmed.ncbi.nlm.nih.gov/14506750/ [11] https://pubmed.ncbi.nlm.nih.gov/14506750/ [12] https://pubmed.ncbi.nlm.nih.gov/9495809/

적용 분야

방법	바이오마커	이미지	PMID
Western blot	c-Jun / α-tubulin / p-ERK / ERK / p-AKT / AKT p-JNK / JNK / Cyclin D1 p-HER2 / HER2 MMP9 / XIAP / VEGF		17482134

기술 지원

취급 설명서

Tel: +1-832-582-8158 Ext:3

다른 문의사항이 있으시면 메시지를 남겨주세요.

자주 묻는 질문

질문 1:
How to formulate this inhibitor for i.p. injection?

답변:
You can prepare the stock of this compound by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):